title: Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Racil
authors.forename: Hana
authors.initials: H
authors.lastname: Klamova
authors.forename: Jaroslava
authors.initials: J
authors.lastname: Voglova
authors.forename: Edgar
authors.initials: E
authors.lastname: Faber
authors.forename: Filip
authors.initials: F
authors.lastname: Razga
authors.forename: Daniela
authors.initials: D
authors.lastname: Zackova
authors.forename: Lucie
authors.initials: L
authors.lastname: Buresova
authors.forename: Petr
authors.initials: P
authors.lastname: Cetkovsky
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000328:Adult; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D013163:Splenomegaly / Q000150:complications*; D017211:Treatment Failure
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate